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An increasing number of calcium oxalate stone events worsens
treatment outcome
JOAN H. PARKS and FREDRIC L. COE
Nephrology Section, University of Chicago, Chicago, Illinois, USA
An increasing number of calcium oxalate stone events worsens treat-
ment outcome. Current practice recommends metabolic evaluation of
patients who have formed multiple renal stones, but not those with one
stone or temporally remote stones. This presumes that recentness and
recurrence imply greater risk of new future stones. We hypothesize that
number of stones reflects how long patients are permitted to form
stones untreated, and that forming more stones, itself, raises risk of
future stones despite treatment. Our report is a retrospective analysis of
371 male patients selected from a comprehensive clinical and laboratory
data base containing 2,527 patients with nephrolithiasis. Before treat-
ment, number of stone events rises with time of observation, and rate of
stone event occurrence is constant or falls. During treatment, relapse is
correlated with number of pretreatment stones. Life table analysis
showed increasing relapse for patients grouped into those with one,
two, and three or more stones. Even though number of stones seems
controlled by the interval of observation before treatment, more stones
predict higher relapse during treatment. Perhaps by leaving nuclei of
crystals as residues, stones appear to promote new stones, and the
practice of waiting while patients declare themselves multiple stone
formers may not always be the best.
The number of stones a patient has formed, and the recent-
ness of new stones, are widely used to assess need for meta-
bolic evaluation and treatment. For example, the NIH Consen-
sus Conference on Nephrolithiasis recommends metabolic
evaluation for adults with two or more stone events, but not for
those with only one event [1]. Pak [2] comments that the
potential benefit of evaluating single stone formers may not
justify the cost. Smith [31 recommends that patients with one
stone, and patients whose stones all occurred in the past, be
given conservative management, and not studied extensively.
The practice of evaluating and treating patients with many and
recent stones, and only counselling patients with single or
temporally remote stones, to maintain high urine volume and
prudent diets, assumes that more and recent stones mean a
greater stone forming propensity within the patient. This pre-
sumption implies either a higher frequency and severity of stone
forming metabolic disorders than would be found among pa-
tients with one stone or no recent stones, or a greater risk that
such disorders will lead to active stone disease if untreated.
The first of these two implications does not accord with what
Received for publication November 8, 1993
and in revised form December 29, 1993
Accepted for publication December 30, 1993
© 1994 by the International Society of Nephrology
we have reported; stone number is not related strikingly to the
accepted metabolic causes of stone formation. Among patients
with only one stone each [4], not divided by sex, we and Pak [5]
found the same metabolic disorders as among patients with
multiple stones, except for less marked hypercalciuria. Among
patients with over 10 stones each, we found no different [6]
mixture, or severity, of metabolic disorders than among all
other patients, except that [7] women with above 10 stones had
higher urine calcium excretion rates than women with less than
10 stones, Timing and number of stones do not seem to predict
the outcome of metabolic evaluation.
Our findings do support the second implication, though
indirectly. In our appraisal of factors predicting relapse of
treated stone disease, we [8] reported that the interval between
the last pretreatment stone and the beginning of treatment
predicted relapse: the shorter the interval, the higher the risk of
relapse. Since nucleation of calcium oxalate monohydrate
(COM), the principle stone forming salt [9], requires higher
supersaturations than growth and aggregation [10], any pre-
formed nuclei can foster COM stones. Each stone may deposit
COM nuclei in kidneys or renal papilla, and leave some behind
after passing. Therefore, past stones could foster new stones,
and increase the stone forming response to metabolic abnor-
malities: stone forming, itself, could promote stones.
We hypothesized that the number of stones an untreated
patient forms reflects how long that patient is observed. Longer
intervals permit more stones, and more stones, even if due
simply to longer intervals, increase the likelihood of relapse
during treatment. In the present study, of men stone formers,
we find that the number of stones is dependent upon the interval
of observation, not the stone forming rate. Nevertheless, num-
ber of stones predicts relapse during treatment. That the
number of events predicts relapse, yet reflects mainly how long
the disease is left to progress untreated, supports the idea that
increasing numbers of stones can increase the likelihood of
more stones, despite treatment.
Methods
Patients
From our complete series of 2,527 patients, we selected all
with calcium oxalate stones documented by stone analysis, in
whom we could exclude systemic or renal diseases that cause
stones including: primary hyperparathyroidism [11], enteric
hyperoxaluria, bowel resection or inflammatory bowel disease
[12], primary hyperoxaluria [13, 14], renal tubular acidosis [15],
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and sarcoidosis [16]. We also excluded a patient if any stone
contained struvite [171, cystine [18], or more than 50% uric acid
or calcium phosphate, even if other stones contained only
calcium oxalate. This left 807 calcium oxalate stone formers
free of apparent stone forming systemic diseases. Of these, 508
had received treatment for at least 2.5 months, and were taken
as the group for initial inclusion. In this group, the main
accepted causes of stones included idiopathic hypercalciuria,
hyperuricosuria, hypocitrituna, dietary hyperoxaluria, and low
urine volume [19—21]. The limited number of women (137) did
not permit the kind of analysis we wished to perform, and we
were unwilling to pooi men and women, because we [22—251
have repeatedly described important gender differences in stone
disease. Therefore, we have considered only the 371 men.
Laboratory evaluation
We obtained, at entry, three or four 24-hour urines [19],
collected from outpatients on open diets, in which measure-
ments were made of: calcium, oxalate, uric acid, pH, citrate,
phosphate, sodium, potassium, magnesium, volume, chloride,
sulfate, and creatinine. At the conclusion of each collection,
between 7:30 and 9:00 a.m., 12 hours after the last meal, blood
was measured for calcium, magnesium, phosphate, uric acid,
creatinine, sodium, and potassium. At six to eight weeks of
medical therapy for metabolic disorders, and yearly thereafter,
each of these materials was measured in one urine and blood.
Clinical evaluation
All patients were evaluated clinically by one of us (FLC).
From medical records and history, and reading of all available
radiographs, the time course of new stone formation and
passage was constructed, in which a new stone means the
appearance by radiograph, or the passage or removal, of a stone
not present on a prior radiograph [19, 26]. Each new stone
carried the best available date, which was rounded here to the
nearest day. Each date of a medical record, x-ray, or proce-
dure, whether associated or not with a new stone, was entered
as a data acquisition date, also rounded to the nearest day.
Many stones may occur in one event; especially among
patients who have many stones, clusters of stones may pass
within a day or even hours and may appear on radiographs
separated by only months. Therefore, a data acquisition date
may contain more than one stone, and all new stones within a
given acquisition date carry that one date. Our analysis uses
both events and stone counts. A new stone means a dated
documentation of one or more stones; a new stone means one of
the component stones within an event, which may vary from at
least one to as many as are counted.
Family history and medication history were taken initially
using a formatted patient questionnaire. The questions included
stones in first and second degree relatives, names and durations
of all medications prescribed for stone prevention, and dates
and types of procedures and hospitalizations for stone passage
events. Clinical history was taken directly for each point, using
the question responses as a prompt. New stones in family
members after the initial visit were entered when patients
reported them.
Many patients had treatments offered before they came here,
including medications, high fluid intake, and diet modifications.
Despite an interest in these, we have found patient recollections
and past medical records were fragmentary, at best. In partic-
ular, treatments were vaguely dated, and usually of very brief
duration. We took the long-term strategy of studying patients
on the diets and fluid intakes most consistent with their usual
habits over the preceding years, so that important effects of
either, that could alter urine chemistries, would be detected.
Subsequent to entry, all patients were followed to the degree
possible, treating their metabolic disorders in the usual manner
[8, 19, 20, 27—30]. Using thiazide, potassium alkali salts, allo-
purinol, reduced diet oxalate, purine and sodium, and increased
water, the urine calcium, oxalate and uric acid were reduced
and urine citrate increased to or as close as possible to the
normal range, and raise urine volume to >1.5 liter/day. Data
acquisition dates after entry included all visits, x-rays, stone
passage, changes in medications, and telephone contact with
patients, or their doctors. Data acquisition dates could be
positive or negative for a stone event; positive dates were coded
as relapse.
Compliance during treatment was assessed mainly from
laboratory evaluation, supplemented by visits and telephone
calls. Most patients told us they were compliant, but when
confronted by evident disparities, such as low urine volume,
high urine oxalate, urine citrate and pH that did not rise with
supposed citrate treatment, urine calcium that did not fall with
thiazide, would then admit to a certain lack of consistency. For
this reason, urine chemistries were rechecked after one to three
months of treatment and yearly thereafter. The full range of
treatment data is shown, as what we believe is the most reliable
and objective measure of compliance and effectiveness of
treatment.
Laboratory methods
Calcium and magnesium were measured by atomic absorp-
tion, uric acid by the uricase method [31], citrate using citrate
lyase [32], sodium and potassium by flame photometry, creati-
nine by the acid picrate method, phosphate by the autoanalyzer
method, oxalate by zinc reduction (until 1990) [33], and oxalate
oxidase (after 1990), pH by electrode.
Statistical methods
All data were kept in a specialized data base using a DataPer-
fect (WordPerfect Corporation, Ogen, Utah, USA) engine.
Patients were selected as noted above, and their data arrays
analyzed using the SYSTAT system (SYSTAT, mc, Evanston,
Illinois, USA). Life table analysis used the Survival module of
Systat; time in the post-treatment period was taken from onset
of treatment to date of last data acquisition; censoring was at
first relapse stone event.
We observed that frequency of events and stones was linear
when plotted as logarithms on half normal plots [34]. Therefore
for all analyses of correlation between either one and metabolic
measurement, for I-tests, and for entering either into propor-
tional hazard models, both the logarithmic and non-transformed
counts of events and stones were used. Our correlation studies
employed corrections for multiple testing, as did our t-testing.
The rate of pretreatment stone forming was calculated as the
number of stones formed, divided by the time in years from the
first stone to entry into our program. Event rates were similarly
calculated.
The majority of men had one to four events (Fig. I) as shown
by the thickness of data clusters at those regions. Stones and
events are presented as logarithms, because both were log
normally distributed (not shown). The overlying plot depicts the
density of points on the plane of the graph as contour lines,
representing five density levels from 0.05 to 0.25 [34] using a
weighting algorithm. Each could, if so drawn, represent an
increasing height above the page. Many patients had one event
with one stone (left lower corner), a subgroup had one event
with two or three stones (along left axis of figure). Another large
group of patients had two events with two to four stones
(second vertical line of points from left side of figure). A third
distinct cluster appears to the right of the cluster at two events,
comprised of patients with three and four events, and up to five
stones. About the three centers, points spread upwards because
events had more than one stone each; below the line of identity,
contour plots circle about each other, by convention, but no
points could be present.
Increasing time of observation, not event rate, correlates
with an increasing number of events (Fig. 2). Mean value of
observation time (open circles, Y axis) rises in proportion to an
increasing number of events, whereas the mean event rate (star
symbols, Y axis) falls or stays constant between two and six
events. The number of events reflects mainly the time of
observation between first stone and the start of treatment, and
is therefore an artifact of how long patients or their doctors
waited before making use of our program. Single stone formers
entered our program shortly after their stones, as shown by the
short interval. Note that the figure presents mean stone event
0
Fig. 1. Numbers of stones and of stone
events among patients with calcium oxalate
nephrolithiasis. Number of stones (y axis) and
stone events (x axis) prior to entering
treatment in men with calcium oxalate
nephrolithiasis. Each point represents one
patient. The contour lines connect regions of
equal density of points. Clusters are apparent
at I and 2 events, and a region bounded by 3
and 4 events.
0 1 2 3 4 5 6 7
Number of events
Fig. 2. Event rate and observation time vs. number of stone events.
Values are Means SEM. Event rate (stars) fell between 1 to 2 events,
then remained constant; number of events (x axis) increased. Years of
observation (open circle) increased in proportion to increasing events.
rates, which are formed for each patient as the ratio of events to
time of observation. Because the ratio of a mean is usually
unequal to the mean of the ratio, one cannot calculate the
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Table 1. Selected clinical and laboratory measurements in relapse
and non-relapse patients
Measurement Relapse No relapse
Number of subjects 71 300
Age at entry years
Age at first stone
40 1
31 1
44 I
35.8 0.6"
Stones in family (%) 30 (42%) 121 (41%)
Follow-up interval years 5.2 0.54 6.8 0.28c
Total stones/pt 5 1 3 i
Number of events/pt 3.75 0.40 2.68 0.15c
Event rate #/year 1.79 0.68 1.38 0.14
Duration of stones years 9.26 0.91 7.7 0.41
Urine volume (liter/24 hr) 1.50 0.07 1.72 005b
Urine [calcium] mg/liter 185 9 162 4b
Urine [oxalate] mg/liter 28 1 24 0.5"
Laboratory measurements are before treatment; during treatment, no
laboratory measurements differed. Stones and events are all pretreat-
ment.
a Interval (years) from onset of treatment to last dated new clinical
information Differs from relapse, I) P < 0.05, <0.02, (1 <0.001
expected mean event rate by simply dividing the number of
events by the mean observation time, nor calculate the correct
mean observation time by multiplying the event number by the
mean event rate.
Since our question concerned relapse, we divided our pa-
tients into those who did and did .ot relapse (Table 1). Men
with relapse were younger, followed up for a shorter interval
after treatment, had more pretreatment stones and stone
events, and lower pretreatment urine volume (Fig. 3A and
Table 1), and correspondingly higher pretreatment calcium and
oxalate concentrations (Table 1) than men who did not relapse.
Calcium and oxalate excretion rates were the same in relapse
and no relapse patients before treatment (Fig. 3A). The fraction
of patients with a family history of stones in first degree
relatives was the same for relapse and non-relapse patients
(Table 1).
No other laboratory measurement during the pretreatment
(Fig. 3A), or treatment periods (Fig. 3B), nor change in any
measurement between pretreatment and treatment intervals
(Fig. 3C) differed between patients who did and did not relapse.
As expected, treatment raised urine pH, urine volume, and
urine citrate, and greatly reduced urine calcium as can be seen
from the graph of changes for their values (Fig. 3C). Changes
for the two groups were not different, and values overlap (Fig.
3C). No correlation coefficient between either stone number or
event number and any of these laboratory measurements was
significant (not shown). Given the overlap of all relevant urine
measurements, classifications of patients into such categories
as hypercalciuria, hyperuncosuna, hyperoxaluria, and hypoc-
itrituria were equivalent, by definition, and are not further
shown. Although our figures (Fig. 3A-C) omit normal ranges,
for clarity, the degree of restoration of all chemistries into the
normal range by treatment was equivalent, as the final values
(Fig. 3B) overlap.
To determine the independent covariates of relapse, we
calculated the Cox proportional hazards model [35, 36] using all
of the variables that differed between those with and those
without relapse (Table 2). Age, pretreatment urine volume, and
the logarithm of total stone events contributed. From the
regression coefficients, we calculated the relative risk (RR,
Table 2) when each of the three prognostic variables was
displaced 1 SD above or below its mean value; this relative risk
is the ratio of the hazard function at the displaced value of the
prognostic variable to the hazard function at the mean value.
When the number of events changes between 0.24 and 4.4
events, for example, a swing of 2 SD, risk rises by 2.85; in
contrast, increasing age or increasing urine volume before
treatment reduces risk.
Given the important predictive value of pretreatment event
number for relapse, and that the numbers of events in our
population were clustered into one, two, and three or more
(Fig. 1), we divided our patients into those having one, two, or
three or more events to determine if this division accurately
predicted relapse. Non-parametric survival curves (Fig. 4) for
the three groups separate clearly, and differ by log rank testing
(P < 0.001 for Mantel-Haenszel, Breslow-Gehan, and Tarone-
Ware chi square statistics).
As expected (Table 3), the three groups differ in number of
pretreatment stones, and the fraction of patients who relapsed
was highest in Group 3, lowest in Group 1 ( = 10.2, P < 0.01).
Age no longer varied smoothly with relapse. As in the pooled
analysis of Figure 1, time of observation increased with number
of stone events in each group, and rate decreased between one
and two events. Urine pH during treatment was highest in
Group 3. A proportional hazard analysis of the seven observa-
tions (excluding relapse fraction) that differed among the three
groups (Table 3), revealed total stones formed [0.02 regression
coefficient (0.005 to 0.034 95% CI), P = 0.008] and age [—0.026,
(—0.053 to —0.003 95% CI), P = 0.026] as significant. In other
words, even after grouping by event number, number of stones
itself offered an additional prediction of relapse, as did younger
age.
Discussion
The majority of male stone patients studied had had between
one and five episodes of new stones between the beginning of
their disease and the time their treatment began, and within this
interval the number of events correlated mainly with the time
between onset of disease and treatment, not differences in stone
forming rate. Even though the number of events reflected time
of observation, and the latter depended upon when patients and
their doctors chose to use our program, the number of events
predicted outcome of treatment, whereas accepted urinary
stone risk factors [30] such as urine calcium, oxalate, and
citrate did not, and left as remaining independent predictors
only age and pretreatment urine volume.
We suggest, for men, at least, that increasing numbers of
stones somehow promote more stones, despite treatments that
reduce urine supersaturation, such as thiazide, citrate and
water, or reduce nucleation such as Allopurinol or reduced
dietary purine levels. Our past results [8] seem rather prescient,
in that a short interval between start of treatment and the last
new stone predicted relapse during treatment, as though a
recent stone had somehow affected treatment outcome. Possi-
bly, repeated stones deposit nucleation centers within tubules
or on urinary surfaces [37]. Crystals may adhere to renal cells,
damage them, and set up nucleation sites [38]. Many stones
may simply increase risk that tiny new stones will be present at
the start of treatment, too small to see on radiographs, yet able
to grow or even nucleate new crystals, and appear later as
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Fig. 3. Pretreatment (A), during treatment
(B), and d(fference between pretreatment and
treatment (C) for 6 major urinary stone risk
factors. Lower portions of each plot represent
1500 non-relapsing patients, upper points those
with relapse. Mean values for pretreatment
urine volume, urine calcium concentration and
urine oxalate concentration differed between
relapse and non relapse patients, and are in
Table 1. No other values differed between
groups. All values for changes (Fig. 3c)
differed significantly from zero except for fall0 in urine oxalate, relapse patients. Normal
mean values for men 1 SD are: calcium 169' 146 mg/24 hr; citrate 531 416 mg/24 hr;
700 800 oxalate 35 17 mg/24 hr; volume 1.27 104
liter/24 hr; uric acid 0.674 0.330 g/24 hr, pH
6.01 0.05.
"new" stones. All of these seem reasonable hypotheses for
other investigations.
Our finding that time of observation controls the numbers of
stone events is consistent with a lack of correlation between
number of stone events and metabolic stone risk factor mea-
surements [4, 6, 7]. If the number of stone events reflects
mainly time of observation, then no correlation would be
expected. Patients can be considered as reasonably homoge-
neous in stone forming propensity, and merely permitted vary-
ing times to express that propensity.
A number of objections to our conclusion must be consid-
ered. One might hypothesize that our patients with many stones
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failed on treatment elsewhere before referral to us, and are
therefore selected as treatment resistant, However, we found
that treatment efforts before referral were of little significance.
Of the 371 patients, only 10 received any treatments apart from
diet advice, and of these, only five took sustained treatment for
more than three months. One might conjecture that patients
with many stones were less vigorously treated here than those
with one stone, but recurrent stone formers were always offered
the same or more vigorous treatments in our program than
those with only one stone. It seems unlikely, therefore, that
selective undertreatment of patients with many pretreatment
stones could have caused more relapse in this group. Low
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calcium diet, suspected as a cause of increased stones [39], is
not used in our program because of risk of bone disease [40—44].
Our follow-up program is fixed at six weeks and yearly there-
after for all patients, and those with more pretreatment stones
did not receive higher follow-up measurement rates; this ex-
cludes systematic overcounting of relapse among them from
greater surveillance. Our data presented here absolutely ex-
clude differences in all measured urine stone risk factors except
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Table 2. Independent covariates of relapse estimated by Cox proportional hazards method
Prognostic
Variable
Regression
Coefficient P Max LL
RR Ratio
of
RisksLow High
Log # of events 0.776 (.445 to 1.108) 0.000 —345.766 0,592 1.688 2.85
Age years —0.029 (— .053 to — .005) 0.019 —342.710 0.727 1.374 1.89
Urine volume liter/day
—0.376 (— .805 to .053) 0.086 —340.999 0.752 1.33 1.76
Regression coefficients have units of (1/the variable), and are shown with 95% confidence intervals in parentheses. P values are two sided
significance levels for coefficients. The P value for regression including all variables shown is <0.001; Abbreviations are: Max LL, log likelihood
(LL) estimate of regression fit; starting value for LL is 354.3. RR, ratio of hazard function for values of prognostic variable 1 SD below or above
mean values to the value of the hazard function at the mean value; RR low is the ratio when the variable is displayed I SD in the direction that
reduces risk, that is, less events, higher age or volume; RR high is the opposite; ratio of risks is the ratio of RR values, high/low, for example an
increase of age from 1 SD unit below to 1 SD unit above the mean increases risk of relapse by 1.89, or 89%; mean values for prognostic variables
with SD are: Log # events, 0.81 0.68 (2.24 2 events); age, 42.8 Il years; urine volume before treatment, 1.67 .76 liter/day.
as noted. We find it curious that urine volume before treatment
predicts relapse, yet urine volume during treatment does not.
We cannot explain this. Finally, family history of stones is
associated with relapse [45]; however, family history of stones
occurred to an exactly equal extent in relapse and non-relapse
patients in this study.
The clinical implications of our study, if correct, must affect
practice. If increasing numbers of events worsen prognosis for
men during treatment, and if increasing time from first stone
permits an increasing number of events, early intervention after
even one stone event may be a better prevention strategy than
permitting patients to form more stones, and thereby "prove"
themselves chronic stone producers. In a township study [461
most patients with single stones had recurrences. We found the
number of events and number of stones were independent
Measurement Group I Group 2 Group 3
Number of patients 114 96 161
Number (%) with 12 (10.5) 17 (17.7) 42 (26.1)
relapse
Number of 3.36 0.92 6.9 1.6 10.1 l.4c
pretreatment
stones per patient
Age years
Time from 1st stone
42 1
2.91 0.48
41 1
7.13 0.6c
44 1
12.1 0.5
to entry years
Rate (stones/year) 4.91 0.81 2.09 0.63c 2.25 0.92a
Time of follow-up 7.4 0.5 6.4 0.5 5.9 04b
years
Age at first stone 39.3 1.1 33.9 1.1" 32.2 0.7c
years
Urine pH during 6.19 0.04 6.28 0.05 6.31 0.04"
treatment
correlates of relapse; this supports the natural clinical instinct
to view a patient with an event containing 20 stones as "more
active" than a patient with only one stone in an event, and
supports the practice of evaluating patients with multiple stones
and one event. We do not understand what determines number
of stones per event.
The idea that stones are autocatalytic also supports the idea
that dormant or temporally remote stones may well be best left
untreated. Once the process ceases, for whatever reason, it
may not reignite. On the other hand, given even one recent
stone, efforts at prevention are not unreasonable. These may,
indeed, take the form of diet or minimal uses of active medica-
tions, as one stone offers a better prognosis than many stones.
The actual outcome of prospective studies that segregate single
but recent stone formers could be very useful for guiding
practice in this difficult area. As well, prospective trials of stone
treatments may well benefit from stratified randomization on
event number. Finally, the significance of these results for
females remains uncertain.
Overall, the dogma that single stones require little or no
evaluation or treatment seems potentially wrong. We cannot,
Table 3. Observations that differed among men grouped by number
of stone events
l.0
Cl) 0.8
a>C0
U)
a)0.6
0
a>0.4
C0
0
Ce
U-
0.2
0.0
Fig. 4. Stone relapse among men with treated calcium oxalate neph-
rolithiasis. Open circles are men with one stone event, open triangle
men with two stone events, and closed squares men with three or more
stone events before starting treatment. Empirical Kaplan Meier life
table method.
Time, years
ap< 0.05, bp< 0.01, 0.001 vs. group 1, dp< 0.05, ep<
0.001 vs. group 2
Groups are patients with 1, 2 and 3 or more events, respectively.
Percent relapse differs among the 3 groups, = 10.7, P < 0.01).
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from this study, make universal recommendations about prac-
tice, but certainly the issue of outcome for this type of patient
requires more study given our results. At very least, single
stone formers require careful evaluation for recurrence.
Reprint requests to Joan Parks, Nephrology Section, MC 5100,
University of Chicago, 5841 South Maryland Ave., Chicago, Illinois
60637, USA.
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